Skip Header

 
Contribute Send feedback

Reviewed, UniProtKB/Swiss-Prot O15304 (SIVA_HUMAN)

Last modified December 16, 2008. Version 69. Feed History...

Clusters with 100%, 90%, 50% identity | Documents (2) | Third-party data | Customize display text xml rdf/xml gff fasta
Names and origin · Protein attributes · General annotation (Comments) · Ontologies · Binary interactions · Alternative products · Sequence annotation (Features) · Sequences · References · Cross-references · Entry information · Relevant documents

Names and origin

Protein namesRecommended name:
    Apoptosis regulatory protein Siva
Alternative name(s):
    CD27-binding protein
      Short name=CD27BP
Gene names
Name: SIVA1
Synonyms: SIVA
OrganismHomo sapiens (Human)
Taxonomic identifier9606 [NCBI]
Taxonomic lineageEukaryotaMetazoaChordataCraniataVertebrataEuteleostomiMammaliaEutheriaEuarchontogliresPrimatesHaplorrhiniCatarrhiniHominidaeHomo

Protein attributes

Sequence length175 AA.
Sequence statusComplete.
Sequence processingThe displayed sequence is not processed.
Protein existenceEvidence at protein level.

General annotation (Comments)

Function

Induces CD27-mediated apoptosis. Inhibits BCL2L1 isoform Bcl-x(L) anti-apoptotic activity. Inhibits activation of NF-kappa-B and promotes T-cell receptor-mediated apoptosis. Ref.7 Ref.8 Ref.9 Ref.10 Ref.12

Cofactor

Isoform 1 binds 3 zinc ions. Isoform 2 binds 2 zinc ions.

Subunit structure

Binds through its N-terminal region to the C-terminus of CD27 and to PXMP2/PMP22. Binds to the C-terminus of TNFRSF18/GITR. Isoform 1 binds to BCL2L1/BCLX isoform Bcl-x(L) but not to BAX. Binds to capsid protein VP2 from coxsackievirus B3. Binding of SIVA1 to CD27 can be blocked by VP2. Ref.7 Ref.8 Ref.1 Ref.4 Ref.6 Ref.11

Subcellular location

Cytoplasm. Nucleus. Note= In the nucleus, accumulates in dot-like structures. Ref.9

Tissue specificity

Ubiquitous. Mostly expressed in thymus, testis, ovary, prostate, small intestine and spleen and less in colon.

Post-translational modification

Phosphorylated by ABL2/ARG in response to oxidative stress. Ref.5

Pharmaceutical use

Could be used as a potentiator of cisplatin-based chemotherapy. Enhances cisplatin-mediated apoptosis, even under conditions where cisplatin resistance occurs due to elevated levels of BCL2 or BCL2L1.

Alternative products

This entry describes 2 isoforms produced by alternative splicing. [Align] [Select]
Isoform 1 (identifier: O15304-1)

Also known as: Siva-1;

This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry.
Isoform 2 (identifier: O15304-2)

Also known as: Siva-2;

The sequence of this isoform differs from the canonical sequence as follows:
     40-104: Missing.
Notes: Mouse isoform 2 has been shown (PubMed:9177220) to have no pro-apoptotic activity. However, human isoform 2 has been shown to be capable of inducing apoptosis (PubMed:15034012).

Sequence annotation (Features)

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifier

Molecule processing

Chain1 – 175175Apoptosis regulatory protein Siva
PRO_0000097774

Regions

Region36 – 5520Interaction with BCL2L1 isoform Bcl-x(L) and inhibition of BCL2L1 anti-apoptotic activity
Region105 – 12319Interaction with coxsackievirus B3 VP2

Amino acid modifications

Modified residue341Phosphotyrosine; by ABL2 Ref.5

Natural variations

Alternative sequence40 – 10465Missing in isoform 2.
VSP_007525

Experimental info

Mutagenesis341Y → F: Abolishes phosphorylation and apoptotic activity Ref.5
Mutagenesis531Y → F: No effect on phosphorylation or apoptotic activity Ref.5

Sequences

Sequence LengthMass (Da)Tools
Isoform 1 (Siva-1) [UniParc].

Last modified May 23, 2003. Version 2.
Checksum: DB62B7DF4E6B39B3

FASTA17518,695
        10         20         30         40         50         60 
MPKRSCPFAD VAPLQLKVRV SQRELSRGVC AERYSQEVFE KTKRLLFLGA QAYLDHVWDE 

        70         80         90        100        110        120 
GCAVVHLPES PKPGPTGAPR AARGQMLIGP DGRLIRSLGQ ASEADPSGVA SIACSSCVRA 

       130        140        150        160        170 
VDGKAVCGQC ERALCGQCVR TCWGCGSVAC TLCGLVDCSD MYEKVLCTSC AMFET 

« Hide

Isoform 2 (Siva-2).

Checksum: 6A802C0D5B5CE41E
Show »

11011,778

References

« Hide 'large scale' references
[1]"CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein."
Prasad K.V.S., Ao Z., Yoon Y., Wu M.X., Rizk M., Jacquot S., Schlossman S.F.
Proc. Natl. Acad. Sci. U.S.A. 94:6346-6351(1997) [PubMed: 9177220] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), INTERACTION WITH CD27.
Tissue: Cervix carcinoma and Thymus.
[2]"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
The MGC Project Team
Genome Res. 14:2121-2127(2004) [PubMed: 15489334] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
Tissue: Ovary.
[3]"Characterization of TPA-responsive genes in U937 cells using ordered differential display PCR."
Kang H.S., Park Y.J., Jung H.M., Jun D.Y., Huh T.L., Kim Y.H.
Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 164-175.
Tissue: Monocytic leukemia.
[4]"Apoptosis in coxsackievirus B3-caused diseases: interaction between the capsid protein VP2 and the proapoptotic protein siva."
Henke A., Launhardt H., Klement K., Stelzner A., Zell R., Munder T.
J. Virol. 74:4284-4290(2000) [PubMed: 10756043] [Abstract]
Cited for: INTERACTION WITH COXSACKIEVIRUS B3 VP2.
[5]"The ARG tyrosine kinase interacts with Siva-1 in the apoptotic response to oxidative stress."
Cao C., Ren X., Kharbanda S., Koleske A., Prasad K.V.S., Kufe D.
J. Biol. Chem. 276:11465-11468(2001) [PubMed: 11278261] [Abstract]
Cited for: PHOSPHORYLATION AT TYR-34, MUTAGENESIS OF TYR-34 AND TYR-53.
[6]"The apoptotic capability of coxsackievirus B3 is influenced by the efficient interaction between the capsid protein VP2 and the proapoptotic host protein Siva."
Henke A., Nestler M., Strunze S., Saluz H.-P., Hortschansky P., Menzel B., Martin U., Zell R., Stelzner A., Munder T.
Virology 289:15-22(2001) [PubMed: 11601913] [Abstract]
Cited for: INTERACTION WITH COXSACKIEVIRUS B3 VP2.
[7]"Siva-1 binds to and inhibits BCL-X(L)-mediated protection against UV radiation-induced apoptosis."
Xue L., Chu F., Cheng Y., Sun X., Borthakur A., Ramarao M., Pandey P., Wu M., Schlossman S.F., Prasad K.V.S.
Proc. Natl. Acad. Sci. U.S.A. 99:6925-6930(2002) [PubMed: 12011449] [Abstract]
Cited for: FUNCTION, INTERACTION WITH BCL2L1.
[8]"The Siva-1 putative amphipathic helical region (SAH) is sufficient to bind to BCL-XL and sensitize cells to UV radiation induced apoptosis."
Chu F., Borthakur A., Sun X., Barkinge J., Gudi R., Hawkins S., Prasad K.V.S.
Apoptosis 9:83-95(2004) [PubMed: 14739602] [Abstract]
Cited for: FUNCTION, INTERACTION WITH BCL2L1.
[9]"Siva-1 and an alternative splice form lacking the death domain, Siva-2, similarly induce apoptosis in T lymphocytes via a caspase-dependent mitochondrial pathway."
Py B., Slomianny C., Auberger P., Petit P.X., Benichou S.
J. Immunol. 172:4008-4017(2004) [PubMed: 15034012] [Abstract]
Cited for: FUNCTION, SUBCELLULAR LOCATION.
[10]"Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2."
Chu F., Barkinge J., Hawkins S., Gudi R., Salgia R., Kanteti P.V.S.
Cancer Res. 65:5301-5309(2005) [PubMed: 15958577] [Abstract]
Cited for: FUNCTION, POSSIBLE PHARMACEUTICAL USE.
[11]"The zinc containing pro-apoptotic protein siva interacts with the peroxisomal membrane protein pmp22."
Nestler M., Martin U., Hortschansky P., Saluz H.-P., Henke A., Munder T.
Mol. Cell. Biochem. 287:147-155(2006) [PubMed: 16683188] [Abstract]
Cited for: ZINC-BINDING, INTERACTION WITH CD27 AND PXMP2.
[12]"Siva-1 negatively regulates NF-kappaB activity: effect on T-cell receptor-mediated activation-induced cell death (AICD)."
Gudi R., Barkinge J., Hawkins S., Chu F., Manicassamy S., Sun Z., Duke-Cohan J.S., Prasad K.V.S.
Oncogene 25:3458-3462(2006) [PubMed: 16491128] [Abstract]
Cited for: FUNCTION.
+Additional computationally mapped references.

Cross-references

Sequence databases

U82938 mRNA. Translation: AAC51372.1. Different initiation.
AF033111 mRNA. Translation: AAD50057.1. Different initiation.
BC034562 mRNA. Translation: AAH34562.1.
AF401214 mRNA. Translation: AAL02171.1.
BK000018 Genomic DNA. Translation: DAA01049.1.
RefSeqNP_006418.2.
NP_068355.1.
UniGeneHs.112058

3D structure databases

ModBaseSearch...

Protein-protein interaction databases

IntActO15304. 6 interactions.

PTM databases

PhosphoSiteO15304.

Proteomic databases

PRIDEO15304.

Genome annotation databases

EnsemblENSG00000184990. Homo sapiens. [Contig view]
GeneID10572.
KEGGhsa:10572.

Organism-specific databases

GeneCardsGC14P104291.
H-InvDBHIX0012018.
HGNCHGNC:17712. SIVA1.
MIM605567. gene.
GenAtlasSearch...

Phylogenomic databases

HOGENOMO15304.
HOVERGENO15304.

Gene expression databases

ArrayExpressO15304.
CleanExHS_SIVA1.
GermOnlineENSG00000184990. Homo sapiens.

Family and domain databases

InterProIPR008842. Siva_cd27_bd.
[Graphical view]
PfamPF05458. Siva. 1 hit.
[Graphical view]
PIRSFPIRSF038096. Siva_cd27_bd. 1 hit.
ProtoNetSearch...

Other Resources

NextBio40121.
SOURCESearch...

Entry information

Entry nameSIVA_HUMAN
AccessionPrimary (citable) accession number: O15304
Secondary accession number(s): Q96P98, Q9UPD6
Entry history
Integrated into UniProtKB/Swiss-Prot: May 23, 2003
Last sequence update: May 23, 2003
Last modified: December 16, 2008
This is version 69 of the entry and version 2 of the sequence. [Complete history]
Entry statusReviewed (UniProtKB/Swiss-Prot)
Annotation projectHPI (Human Proteome Initiative)

Relevant documents

Human chromosome 14

Human chromosome 14: entries, gene names and cross-references to MIM

MIM cross-references

Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot

Names and origin · Protein attributes · General annotation (Comments) · Ontologies · Binary interactions · Alternative products · Sequence annotation (Features) · Sequences · References · Cross-references · Entry information · Relevant documents